Treatment with nutrition and fluids in patients with non-curable cancer;Ernæring og væskebehandling til pasienter med ikke-kurabel kreftsykdom

Tidsskrift for den Norske Laegeforening

Volumn 126, Issue 5, 2006, Pages 624-627

  Nordøy, Tone ^a,b   Thoresen, Lene ^c   Kvikstad, Anne ^c   Svensen, Rune ^a  

^a Universitetssykehuset Nord Norge ^*  (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMINO ACID; CORTICOSTEROID; GESTAGEN; ICOSAPENTAENOIC ACID; LIPID; METOCLOPRAMIDE; MUSCLE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ANOREXIA; ASTHENIA; CACHEXIA; CANCER; CANCER SURVIVAL; DIET THERAPY; FLUID THERAPY; HUMAN; LIPID DEGRADATION; MALNUTRITION; MUSCLE FUNCTION; NAUSEA; PROTEIN DEGRADATION; REVIEW; STARVATION; WEIGHT REDUCTION; EUROPE; METABOLISM; NEOPLASM; NUTRITIONAL STATUS; NUTRITIONAL SUPPORT; PALLIATIVE THERAPY; PRACTICE GUIDELINE; TERMINAL CARE;

CACHEXIA; EUROPE; FLUID THERAPY; HUMANS; NEOPLASMS; NUTRITIONAL STATUS; NUTRITIONAL SUPPORT; PALLIATIVE CARE; PRACTICE GUIDELINES; TERMINAL CARE;

EID: 33645128734     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Stasser F. Patophysiology of the anorexia/cachexia syndrome. I: Doyle D, Hanks G, Cherny N et al, red. Oxford textbook of palliative medicine. 3. utg. Oxford: Oxford University Press, 2004: 520-33.
2. Dewys WD, Begg C, Lavin PT et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980; 69: 491-7.
3. Bosaeus I, Daneryd P, Lundholm K. Dietary intake, resting energy expenditure, weight loss and survival in cancer patients. J Nutr 2002; 132: 3465S-6.
4. Tisdale MJ. Pathogenesis of cancer cachexia. J Support Oncol 2003; 1: 159-68.
5. Acharyya S, Ladner KJ, Nelsen LL et al. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 2004; 114: 370-8.
6. Klein S, Koretz RL. Nutrition support in patients with cancer: what do the data really show? Nutr Clin Pract 1994; 9: 91-100.
7. Strasser F, Bruera E. Update on anorexia and cachexia. Hematol Oncol Clin North Am 2002; 16: 589-617.
8. Ovesen I, Allingstrup L, Hannibal J et al. Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study. J Clin Oncol 1993; 11: 2043-9.
9. MacDonald N. Anorexia-cachexia syndrome. Eur J Pall Care 2005; 12 (suppl): 8-14.
10. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91: 66-72.
11. Lundholm K, Daneryd P, Bosaues I et al. Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: effects on survival, metabolism and function. Cancer 2004; 100: 1967-76.
12. Bozzetti F, Amadori D, Bruera E et al. Guidelines on artificial nutrition versus hydration in terminal cancer patients. European Association for Palliative Care. Nutrition 1996; 12: 163-7.
13. Bruera E, Kuehn N, Miller M et al. The Edmonton Symptom Assessment System (ESAS): a simple method. J Palliat Care 1991; 7: 6-9.
14. Thoresen L, Fjelstad I, Krogstad K et al. Nutritional status of patients with advanced cancer: the value of using the subjective global assessment of nutritional status as a screening tool. Palliat Med 2002; 16: 33-42.
15. Bruera E, Belzile M, Neumann C et al. A double-blind, crossover study of controlled release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. J Pain Sympt Manage 2000; 19: 427-35.
16. Bruera E, Roca E, Cedaro L et al. Action of oral metylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 1985; 69: 751-4.
17. Lopirinzi C, Kugler JW, Mailliard JA et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 1999; 17: 3299-306.
18. Thomas DA, Kantarjian H. Current role of thalidomide in cancer treatment. Curr Opin Oncol 2000; 12: 564-73.
19. Tisdale MJ. Protein loss in cancer cachexia. Science 2000; 289: 2293-4.
20. Jatoi A, Rowland K, Loprinzi CL et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol 2004; 22: 2469-76.
21. Jatoi A, Windschitl H, Loprinzi C et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-assosiated anorexia: a North Central Cancer Treatment Group Study. J Clin Oncol 2002; 20: 567-73.
22. Walsh D, Nelson KA, Mahmoud FA. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 2003; 11: 137-43.
23. Orr R, Fiatarone Singh M. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety. Drugs 2004; 64: 725-50.
24. Agteresch HJ, Rietveld T, Kerkhofs LG et al. Beneficial effects of adenosine triphosphate on nutritional status in advanced lung cancer patients: a randomized clinical trial. J Clin Oncol 2002; 20: 371-8.
25. May PE, Barber A, D'Olimpio JT et al. Reversal of cancer-related wasting using oral supplementation with a combination of -hydroxy-metylbutyrate, arginine and glutamine. Am J Surg 2002; 183: 471-9.
26. Lundholm K, Gelin J, Hyltander A et al. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 1994; 52: 5602-6.
27. MacDonald N. Is there evidence for earlier intervention in cancer-associated weight-loss? J Support Oncol 2003; 1: 279-86.
28. McCann RM, Hall WJ, Groth-Juncker A. Comfort care for the terminally ill patients. The appropriate use of nutrition and hydration. JAMA 1994; 272: 1263-6.
29. Husebø S. Væskebehandling av pasienter i terminalfasen. Omsorg 1997; 3: 26-30.
30. Ellershaw JE, Sutcliffe JM, Saunders CM. Dehydration and the dying patient. J Pain Symptom Manage 1995; 10: 192-7.
31. Musgrave CF, Bartle N, Opstad J. The sensation of thirst in dying patients receiving iv. hydration. J Palliat Care 1995; 11: 17-21.
32. Bruera E, Franco JJ, Maltoni M et al. Changing pattern of agitated impaired status in patients with advanced cancer: association with cognitive monitoring, hydration and opioid rotation. J Pain Symptom Manage 1995; 10: 287-91.
33. Musgrave CF. Fluid retention and intravenous in the dying. J Pain Symptom Manage 1995; 10: 643-6.